Cantor Fitzgerald Reiterates Neutral on CRISPR Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated a Neutral rating on CRISPR Therapeutics (NASDAQ:CRSP).

August 08, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Eric Schmidt has reiterated a Neutral rating on CRISPR Therapeutics (NASDAQ:CRSP).
The reiteration of a Neutral rating by a reputable analyst suggests that there are no significant changes in the company's outlook. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100